The Evolving Role of PI3K Inhibitors in the Treatment of Follicular Lymphoma

Article

On June 18, 2021, OncLive® brought together a group of oncologists who specialize in the treatment of follicular lymphoma to participate in a virtual workshop to discuss the evolving role of PI3K inhibitors in the treatment of follicular lymphoma. This article summarizes key data about PI3K inhibitors as a therapeutic target as well as insights from stakeholder discussions regarding this topic.

Download PDF
Related Videos
Sarah Sammons, MD
Laura Spring, MD
Laura Spring, MD
Corey J. Langer, MD
John F. Lazar, MD
Rodolfo Bordoni, MD
Brad S. Kahl, MD, of Siteman Cancer Center
John P. Leonard, MD, of Weill Cornell Medicine
John P. Leonard, MD, of Weill Cornell Medicine
Related Content
Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

April 21st 2023
Article
Clinical Decision Making in Advanced NSCLC without Actionable Mutations

Clinical Decision Making in Advanced NSCLC without Actionable Mutations

April 21st 2023
Article
BTK Inhibitors in MCL and CLL

BTK Inhibitors in MCL and CLL

March 10th 2023
Article
Where Do ADCs Fit Into the Treatment Paradigm for Patients With NSCLC?

Where Do ADCs Fit Into the Treatment Paradigm for Patients With NSCLC?

January 25th 2023
Article
Clinical Case Scenarios: Approaches to Treatment Decisions in Non-Small Cell Lung Cancer

Clinical Case Scenarios: Approaches to Treatment Decisions in Non-Small Cell Lung Cancer

January 25th 2023
Article
Advances in the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Advances in the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

December 22nd 2022
Article